Rockwell Medical

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rockwell Medical reports record revenue and eyes global expansion

Rockwell Medical's Q4 2022 earnings call showcased strong revenue growth, operational improvements, and strategic initiatives for future profitability. While challenges in expense optimization and debt reduction persist, the company's focus on growth through international partnerships and new product developments presents promising opportunities. Overall, Rockwell Medical is on track to achieve financial stability and sustained growth in the healthcare market.

Rockwell Medical reports record revenue and progress towards profitability

Rockwell Medical (RMTI) delivered strong Q1 2023 results with record revenue and progress towards profitability. The company's strategic initiatives, including the successful transition of the Baxter business, are driving growth. Despite challenges, Rockwell Medical's focus on cost reduction and business development positions it well for future success.

Rockwell Medical reports Q2 challenges but eyes profitability in 2024

Rockwell Medical's Q2 2023 performance reflects challenges in net sales and profitability but highlights strategic progress towards financial stability and growth.
The company's strengths lie in revenue increase, expense reduction, and the acquisition of Evoqua's business, positioning it for accelerated profitability.
While facing challenges in financial results and product development, Rockwell's focus on market expansion and optimization presents opportunities for future growth and revenue diversification.

Rockwell Medical posts record Q3 sales, eyes profitability in Q4

Rockwell Medical's Q3 performance reflects strong sales growth and strategic acquisitions.
While facing margin challenges, the company's focus on profitability and leadership enhancements bode well.
Opportunities lie in market dominance, operational improvements, and leveraging customer agreements.
Maintaining financial stability and pursuing growth avenues are key priorities for Rockwell's future success.

Rockwell Medical achieves historic profitability and projects strong sales growth

Rockwell Medical's Q4 2023 performance reflects significant milestones with profitability achieved and record net sales reported. The company's strategic focus on operational efficiency, growth projections, and margin improvements indicate a positive trajectory. While challenges persist, Rockwell is well-positioned to leverage opportunities for sustained growth and profitability.

Rockwell Medical reports record Q1 sales and profitability growth

Rockwell Medical delivered robust financial results in Q1 2024, showcasing growth in net sales, gross profit, and improved profitability metrics.
The company's strategic initiatives to enhance margins, optimize operations, and reduce debt position it well for future growth and value creation.
While facing challenges in a competitive market, Rockwell's unique market position and financial discipline provide a solid foundation for sustained success.

Rockwell Medical reports record-high sales and profitability, eyes global expansion

Rockwell Medical's Q3 2024 performance reflects strong financial health, profitability, and record-high sales, underpinned by strategic initiatives and partnerships.
The company faces challenges in customer dynamics but is well-positioned to capitalize on growth opportunities in at-home dialysis and international markets.
With a focus on quality, customer service, and sustainable profitability, Rockwell Medical is poised for continued success and market expansion.
Overall, Rockwell Medical's Q3 2024 earnings call highlights resilience, adaptability, and a positive outlook for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in 1996 and is headquartered in Wixom, MI.

The stock price of Rockwell Medical Inc (NASDAQ: RMTI) increased by over 40% during intraday trading today. This is why it happened.

Rockwell Medical Stock (RMTI): Why The Price Went Up Substantially Today

-Commercial launch expected in June/July 2022-

Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea

WIXOM, Mich., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the Rockwell Medical executive management team is scheduled to present at the H.C. Wainwright BioConnect 2022 Conference.

Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2022 Conference

WIXOM, Mich., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion

Rockwell Medical Inc (NASDAQ: RMTI) has announced the publication of results in the Journal of Bioequivalence & Bioavailability from a study evaluating the co-administration of intravenous (IV) Ferric Pyrophosphate Citrate (FPC, Triferic) with unfractionated heparin (UFH) as an admixture. The study demonstrated no clinically relevant drug-drug interaction (DDI) between FPC and UFH on the effects of UFH nor on the ability of FPC to deliver bioavailable iron when these agents are co-administered as a single admixture via an HD-machine syringe pump.

Why Are Rockwell Medical Shares Surging Wednesday?

The shares of Rockwell Medical Inc (NASDAQ: RMTI) increased by over 55% pre-market today. This is why it happened.

Rockwell Medical (RMTI) Stock: Why The Price Surged Today

Findings confirm results from previous population PK study demonstrating safe and effective anticoagulation along with the delivery of Ferric Pyrophosphate Citrate iron Findings confirm results from previous population PK study demonstrating safe and effective anticoagulation along with the delivery of Ferric Pyrophosphate Citrate iron

Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated Heparin

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q3 2021 Results - Earnings Call Transcript

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -14.29% and -11.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical (RMTI) Reports Q3 Loss, Misses Revenue Estimates

Rockwell Medical (NASDAQ:RMTI) reported its Q3 earnings results on Monday, November 15, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Recap: Rockwell Medical Q3 Earnings

- Third quarter net sales of $16.0 Million, up 6% sequential quarter-over-quarter and 5% year-over-year -

Rockwell Medical, Inc. Provides Third Quarter 2021 Financial and Operational Update

WIXOM, Mich., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

Rockwell Medical Submits Investigational New Drug Application with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion

-Results from pilot observational analysis demonstrate maintenance of hemoglobin and reduction of total IV iron requirement in adult patients on Triferic receiving chronic hemodialysis-

Rockwell Medical Presents Triferic® Real World Evidence Update at ASN Kidney Week 2021

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Rockwell Medical (RMTI) Report Negative Q3 Earnings? What You Should Know

Management continues to invest behind its FPC drug platform.

Rockwell Medical: Down But By No Means Out

WIXOM, Mich., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members of its executive management team are scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

Rockwell Medical, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WIXOM, Mich., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company's Board of Directors approved the grant of an option to purchase 350,000 shares of the Company's common stock to Megan C. Timmins, the Company's Senior Vice President, General Counsel and Secretary (the “Inducement Grant”). The Inducement Grant has been granted outside of the Company's 2018 Long Term Incentive Plan (“Plan”), but remains subject to the terms and conditions of such Plan. The Inducement Grant was granted as an inducement material to such individual's entering into employment with Rockwell Medical in accordance with Nasdaq Listing Rule 5635(c)(4).

Rockwell Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q2 2021 Results - Earnings Call Transcript

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -12.50% and -11.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical (RMTI) Reports Q2 Loss, Misses Revenue Estimates

Shares of Rockwell Medical (NASDAQ:RMTI) fell 12.6% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 0.00% over the past year to ($0.09), which missed the estimate of ($0.08).

Recap: Rockwell Medical Q2 Earnings

-Entered into exclusive license agreement with Drogsan Pharmaceuticals for the rights to commercialize Triferic® in Turkey-

Rockwell Medical, Inc. Provides Second Quarter 2021 Financial and Operational Update

China Online Education Group

Ceragon Networks

NuCana

Here's a list of interesting penny stocks to buy that have lucrative prospects if you're willing to risk it for tremendous upside. The post 7 Penny Stocks to Buy if You Want Potential Multibaggers appeared first on InvestorPlace.

7 Penny Stocks to Buy if You Want Potential Multibaggers

Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

WIXOM, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has submitted a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (FDA) in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

Rockwell Medical, Inc. Files Pre-IND Meeting Request with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion

- With approximately 65,000 patients receiving hemodialysis annually, Turkey represents a significant and expanding market opportunity - - With approximately 65,000 patients receiving hemodialysis annually, Turkey represents a significant and expanding market opportunity -

News for Rockwell Medical Stock (RMTI)